Elevation Oncology Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
34
- Stock Symbol
-
ELEV
- Investments
-
1
- Share Price
-
$0.30
- (As of Friday Closing)
Elevation Oncology General Information
Description
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Contact Information
Website
www.elevationoncology.comCorporate Office
- 888 7th Avenue
- 12th Floor
- New York, NY 10106
- United States
Corporate Office
- 888 7th Avenue
- 12th Floor
- New York, NY 10106
- United States
Elevation Oncology Stock Performance
As of 21-Mar-2025, Elevation Oncology’s stock price is $0.30. Its current market cap is $17.8M with 59.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.30 | $0.28 | $0.24 - $5.83 | $17.8M | 59.1M | 2.51M | -$0.78 |
Elevation Oncology Financials Summary
As of 31-Dec-2024, Elevation Oncology has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (38,789) | (38,789) | (42,068) | (56,455) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (45,621) | (45,621) | (45,406) | (94,528) |
| Net Income | (44,485) | (44,485) | (45,704) | (95,080) |
| Total Assets | 95,626 | 95,626 | 89,091 | 94,161 |
| Total Debt | 31,134 | 31,134 | 30,137 | 29,435 |
Elevation Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Elevation Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Elevation Oncology Comparisons
Industry
Financing
Details
Elevation Oncology Competitors (101)
One of Elevation Oncology’s 101 competitors is Nurix Therapeutics, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Enanta Pharmaceuticals | Formerly VC-backed | Watertown, MA |
Elevation Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Elevation Oncology Patents
Elevation Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220288204-A1 | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions | Pending | 11-Mar-2021 | ||
| EP-4304636-A1 | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions | Pending | 11-Mar-2021 | ||
| US-9345766-B2 | Combination therapies comprising anti-erbb3 agents | Active | 30-Aug-2012 | ||
| US-20140079703-A1 | Combination therapies comprising anti-erbb3 agents | Active | 30-Aug-2012 | ||
| US-20190119401-A1 | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | Inactive | 11-Mar-2010 | C07K16/32 |
Elevation Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Elevation Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Elevation Oncology Investments (1)
Elevation Oncology’s most recent deal was a Corporate Asset Purchase with Merrimack Pharmaceuticals (anti-HER3 programs). The deal was made on 01-Jul-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals (anti-HER3 programs) | 01-Jul-2019 | Corporate Asset Purchase | Buildings and Property |
Elevation Oncology ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
34.48 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Biotechnology
Subindustry
of 465
Rank
Percentile
Elevation Oncology FAQs
-
When was Elevation Oncology founded?
Elevation Oncology was founded in 2019.
-
Where is Elevation Oncology headquartered?
Elevation Oncology is headquartered in New York, NY.
-
What is the size of Elevation Oncology?
Elevation Oncology has 34 total employees.
-
What industry is Elevation Oncology in?
Elevation Oncology’s primary industry is Drug Discovery.
-
Is Elevation Oncology a private or public company?
Elevation Oncology is a Public company.
-
What is Elevation Oncology’s stock symbol?
The ticker symbol for Elevation Oncology is ELEV.
-
What is the current stock price of Elevation Oncology?
As of 21-Mar-2025 the stock price of Elevation Oncology is $0.30.
-
What is the current market cap of Elevation Oncology?
The current market capitalization of Elevation Oncology is $17.8M.
-
Who are Elevation Oncology’s competitors?
Nurix Therapeutics, Instil Bio, Kite Pharma, Mersana Therapeutics, and Enanta Pharmaceuticals are some of the 101 competitors of Elevation Oncology.
-
What is Elevation Oncology’s annual earnings per share (EPS)?
Elevation Oncology’s EPS for 12 months was -$0.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
